| Symbol | OMER |
|---|---|
| Name | OMEROS CORP |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 201 ELLIOTT AVENUE WEST, SEATTLE, WA 98119 |
| Telephone | 206-676-5000 |
| Fax | — |
| — | |
| Website | https://www.omeros.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001285819 |
| Description | Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntingtons disease and cognitive impairment; and addictive and compulsive disorders. Additional info from NASDAQ: |
OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
Read moreOmeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA
Read moreDirector Shah Rajiv 🟢 acquired 15.0K shares (1 derivative) of OMEROS CORP (OMER) at $10.28 Transaction Date: Jun 18, 2026 | Filing ID: 021240
Read moreDirector Perkinson Diana T. 🟢 acquired 15.0K shares (1 derivative) of OMEROS CORP (OMER) at $10.28 Transaction Date: Jun 18, 2026 | Filing ID: 021239
Read moreDirector Hood Leroy E. MD PhD 🟢 acquired 15.0K shares (1 derivative) of OMEROS CORP (OMER) at $10.28 Transaction Date: Jun 18, 2026 | Filing ID: 021238
Read moreDirector HANISH ARNOLD C 🟢 acquired 15.0K shares (1 derivative) of OMEROS CORP (OMER) at $10.28 Transaction Date: Jun 18, 2026 | Filing ID: 021237
Read moreDirector Demopulos Peter A MD 🟢 acquired 15.0K shares (1 derivative) of OMEROS CORP (OMER) at $10.28 Transaction Date: Jun 18, 2026 | Filing ID: 021236
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04247906 | Single Patient Expanded Access Treatment Plan For The Investigational Product N… | — | Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA) | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT06209736 | Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN | Phase2 | C3 Glomerulopathy | Recruiting | 2024-03-01 | 2026-04-01 | ClinicalTrials.gov |
| NCT06298955 | Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal H… | Phase2 | Paroxysmal Nocturnal Hemoglobinuria | Recruiting | 2024-02-19 | 2027-04-01 | ClinicalTrials.gov |
| NCT05855083 | Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk H… | Phase2 | Thrombotic Microangiopathies | Recruiting | 2023-05-01 | 2025-12-01 | ClinicalTrials.gov |
| NCT05972967 | Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients W… | Phase2 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2023-03-27 | 2024-10-10 | ClinicalTrials.gov |
| NCT05889299 | Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturna… | Phase1 | Paroxysmal Nocturnal Hemoglobinuria | Unknown | 2022-12-09 | 2024-06-30 | ClinicalTrials.gov |
| NCT04829799 | Effect of Intracameral Phenylephrine/Ketorolac on Intraoperative Pain | Phase4 | Pain Reduction | Withdrawn | 2022-02-01 | 2023-08-01 | ClinicalTrials.gov |
| NCT03864133 | No Drop Post-Op Cataract Surgery | Phase4 | Cataract | Completed | 2019-07-08 | 2021-08-16 | ClinicalTrials.gov |
| NCT03205995 | Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic … | Phase3 | Thrombotic Microangiopathies | Terminated | 2018-05-02 | 2021-02-02 | ClinicalTrials.gov |
| NCT03608033 | Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (I… | Phase3 | IgA Nephropathy | Terminated | 2018-04-05 | 2024-01-12 | ClinicalTrials.gov |
| NCT02682407 | Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disea… | Phase2 | IgAN | Terminated | 2016-03-10 | 2020-08-25 | ClinicalTrials.gov |
| NCT02222545 | Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathi… | Phase2 | Thrombotic Microangiopathies | Completed | 2014-11-02 | 2020-08-11 | ClinicalTrials.gov |
| NCT02132312 | A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilat… | Phase3 | Unilateral Cataract Extraction | Completed | 2014-07-01 | 2016-09-12 | ClinicalTrials.gov |
| NCT02093689 | Intraoperative Floppy Iris Syndrome Undergoing Intraocular Lens Replacement Sur… | Phase3 | Intraocular Lens Replacement | Terminated | 2014-02-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT02074410 | Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease | Phase2 | Huntington's Disease | Terminated | 2014-01-01 | 2014-10-15 | ClinicalTrials.gov |
| NCT01952132 | Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stab… | Phase2 | Schizophrenia | Completed | 2013-09-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01579565 | Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocu… | Phase3 | Intraocular Lens Replacement | Completed | 2012-04-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01454063 | Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replaceme… | Phase3 | Intraocular Lens Replacement | Completed | 2011-09-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01406561 | Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to … | Phase3 | Meniscal Tear | Completed | 2011-08-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01395797 | Pioglitazone for Heroin and for Nicotine Dependence | Phase1 | Heroin Dependence | Terminated | 2011-03-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01395784 | Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability o… | Phase2 | Opioid Abuse | Completed | 2010-08-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01193127 | Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extrac… | Phase2 | Cataract | Completed | 2010-07-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00857090 | Pharmacokinetic, Safety and Efficacy Study of OMS201 in Subjects Undergoing Ret… | Phase1 | Urinary Calculi | Completed | 2009-03-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00721695 | Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Catarac… | Phase1 | Cataract Extraction | Completed | 2008-05-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00624845 | Double-Blind, Multicenter, Study Comparing the Efficacy and Safety of OMS103HP … | Phase2 | Postoperative Pain | Completed | 2007-12-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00599664 | Pharmacokinetic and Safety Study of OMS201 in Subjects Undergoing Ureteroscopic… | Phase1 | Urinary Calculi | Completed | 2007-12-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00226772 | Efficacy and Safety of OMS103HP in Patients Undergoing Autograft Anterior Cruci… | Phase3 | Knee Injuries | Completed | 2005-06-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00226759 | Efficacy and Safety of OMS103HP in Patients Undergoing Allograft Anterior Cruci… | Phase3 | Knee Injuries | Completed | 2004-11-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00245271 | Safety of OMS103HP in Patients Undergoing Anterior Cruciate Ligament (ACL) Reco… | Phase3 | Anterior Cruciate Ligament Reconstruction | Completed | 2004-10-01 | 2011-03-01 | ClinicalTrials.gov |